ACE2 and COVID-19: Moreover, the tolerability of an enzymatically active ACE2-based therapeutic agent was already demonstrated in healthy subjects (61) and patients with acute respiratory distress syndrome (62), pulmonary arterial hypertension (63), or COVID-19 (64).